文献速递白血病

初治CML-CP患者TKI相关严重血细胞减少的影响因素

[Variables associated with severe cytopenia in adult chronic phase chronic myeloid leukemia patients receiving initial tyrosine kinase inhibitors].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

二代TKI组4级血细胞减少发生率显著高于伊马替尼组(7.3%对2.7%,P=0.001)。女性、HGB低、WBC高(或脾大)是严重血细胞减少的危险因素。

要点

  • TKI治疗中位1个月时9.8%患者发生≥3级血细胞减少,以血小板减少为主。
  • 二代TKI组4级血细胞减少发生率7.3%,显著高于伊马替尼组的2.7%。
  • 女性、HGB低、WBC高或脾大为严重血细胞减少的危险因素。

核心结论

  • 严重血细胞减少是CML-CP患者TKI治疗的常见不良事件。
  • 二代TKI的4级血细胞减少发生率高于伊马替尼。
  • 女性、HGB低、WBC高和脾大是TKI相关严重血细胞减少的影响因素。

研究设计与样本

  • 采用二元Logistic回归分析严重血细胞减少(CTCAE 5.0分级≥3级白细胞或血小板减少)的影响因素。

主要发现

  • 186例(9.8%)在中位治疗1(0.2~3)个月发生≥3级血细胞减少,以血小板减少为主,持续0.6(0.1~10.6)个月。
  • 4级血细胞减少68例(3.6%)。
  • 三种TKI间≥3级血细胞减少发生率差异无统计学意义。
  • 二代TKI组4级血细胞减少发生率7.3%,高于伊马替尼组的2.7%(P=0.001)。

关键数值与推荐

  • 严重血细胞减少按CTCAE 5.0分级,关注≥3级白细胞或血小板减少。
  • 伊马替尼组按危险因素分为低危和高危两组,二代TKI组分为低危、中危和高危三组。
  • 各危险分组间≥3级和4级血细胞减少发生率差异均有统计学意义(均P<0.001)。

临床怎么用

  • 对具有女性、HGB低、WBC高或脾大危险因素的高危患者,TKI治疗早期应严密监测血常规。
  • 使用二代TKI时需关注4级血细胞减少风险,尤其是高危组患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To explore the variables associated with severe cytopenia in patients with chronic phase chronic myeloid leukemia (CML-CP) receiving initial tyrosine kinase inhibitor (TKI) therapy. Methods: Data from consecutive patients aged ≥18 years with CML-CP who received imatinib, nilotinib, or flumatinib at Peking University People's Hospital between November 2006 and January 2025 were retrospectively reviewed. Binary logistic regression models were applied to analyze the variables associated with severe cytopenia (according to Common Terminology Criteria for Adverse Events version 5.0, with a focus on grade 3/4 leukocytopenia or thrombocytopenia) . Results: This study included 1 906 patients initially receiving imatinib (n=1 542, 80.9%), nilotinib (n=256, 13.4%), and flumatinib (n=108, 5.7%). The median age was 41 (range, 18-83) years, and 1 141 (59.9%) patients were male. At a median of 1 (range, 0.2-3) month, 186 (9.8%) patients developed grade 3/4 cytopenia, primarily thrombocytopenia, and persisted for 0.6 (range, 0.1-10.6) months, including 68 (3.6%) patients who developed grade 4 cytopenia. No significant difference in the incidence of grade 3/4 cytopenia was observed among patients receiving the three TKIs, whereas grade 4 cytopenia was more common in those receiving the second-generation (2G) TKI (nilotinib and flumatinib) compared with imatinib (7.3% vs 2.7%, P=0.001). Multivariate analysis revealed that female sex, decreased hemoglobin level, and increased white blood cell count (or splenomegaly) were significantly associated with the higher incidence of severe cytopenia in patients receiving TKI. Based on the adverse variables, patients receiving imatinib were categorized into low- and high-risk groups, and those receiving 2G-TKI were classified into low-, medium-, and high-risk groups with a significant difference in the incidence of grades 3/4 and 4 cytopenia (P<0.001) . Conclusion: Severe cytopenia is a common adverse event in patients with CML-CP receiving TKI therapy. Grade 4 cytopenia is more common in those receiving 2G-TKI compared with imatinib. High-risk factors for severe cytopenia associated with TKIs included female sex, decreased hemoglobin level, increased white blood cell count, and splenomegaly at initial diagnosis. Close monitoring is necessary during the early phase of TKI-therapy for the high-risk group. 目的: 探讨初发慢性髓细胞性白血病慢性期(CML-CP)患者服用酪氨酸激酶抑制剂(TKI)期间发生严重血细胞减少的影响因素。 方法: 纳入2006年11月至2025年1月在北京大学人民医院确诊并服用伊马替尼、尼洛替尼或氟马替尼的成人CML-CP连续病例。采用二元Logistic回归模型分析发生严重血细胞减少(按CTCAE5.0分级,关注≥3级白细胞或血小板减少)的影响因素。 结果: 共收集1 906例患者数据,中位年龄41(18~83)岁,男性1 141例(59.9%),一线服用伊马替尼1 542例(80.9%),尼洛替尼256例(13.4%),氟马替尼108例(5.7%)。186例(9.8%)患者在TKI中位治疗1(0.2~3)个月发生严重血细胞减少,且以血小板减少为主,其中4级血细胞减少68例(3.6%),持续0.6(0.1~10.6)个月。三种TKI治疗组≥3级血细胞减少的发生率差异无统计学意义,但二代TKI组(包括尼洛替尼和氟马替尼)4级血细胞减少发生率相较伊马替尼组显著升高(7.3%对2.7%,P=0.001)。多因素分析显示,女性、HGB低和WBC高(或脾大)是TKI相关的严重血细胞减少的危险因素。根据危险因素将服用伊马替尼患者分为低危和高危两组,将服用二代TKI患者分为低危、中危和高危三组,各组≥3级和4级血细胞减少发生率差异均有统计学意义(均P<0.001)。 结论: 严重血细胞减少是TKI治疗的CML-CP患者常见的不良事件,二代TKI 4级血细胞减少发生率更高。女性、HGB低、WBC高和脾大是TKI相关严重血细胞减少的影响因素。针对高危人群在治疗早期应严密监测。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Chai GR, Yu L, Li ZR, et al. [Variables associated with severe cytopenia in adult chronic phase chronic myeloid leukemia patients receiving initial tyrosine kinase inhibitors]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 41991309. doi:10.3760/cma.j.cn121090-20251023-00478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。